Загрузка...
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) a...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Landes Bioscience
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3382866/ https://ncbi.nlm.nih.gov/pubmed/22737621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.18804 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|